Skip to main content

Table 3 Safety of Bevacizumab plus Paclitaxel (total patients n= 35)

From: Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy

Toxicity

Grade 1

Grade 2

Grade 3

Grade 4

n(%)

n(%)

n(%)

n(%)

Bleeding

1 (2.8)

-

1 (2.8)

-

Protenuria

-

-

-

-

Hypertension

-

2 (5.7)

 

-

Neurotoxicity

1 (2.8)

2 (5.7)

-

-

LVS disfunction

1 (2.8)

-

-

-